Patents Assigned to Phigenix, Inc
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 11033628
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: June 15, 2021
    Assignee: PHIGENIX, INC.
    Inventor: Carlton D. Donald
  • TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS
    Publication number: 20140336130
    Abstract: The present invention relates to the compositions and use of compositions for treating a prostate condition in a subject. The use of composition comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Application
    Filed: December 5, 2011
    Publication date: November 13, 2014
    Applicant: PHIGENIX, INC.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
    Patent number: 8735365
    Abstract: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: May 27, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS
    Publication number: 20140135378
    Abstract: The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Application
    Filed: January 16, 2014
    Publication date: May 15, 2014
    Applicant: Phigenix, Inc.
    Inventor: Carlton D. DONALD
  • Detecting PAX2 for the diagnosis of breast cancer
    Patent number: 8722367
    Abstract: A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio (the “Donald Predictive Factor” or “DPF”) in cells obtained from the breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with breast conditions. Also disclosed is a kit for monitoring breast conditions and determining drug resistance.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: May 13, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
    Patent number: 8722643
    Abstract: The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: May 13, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 8653021
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: February 18, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 8633149
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: January 21, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Detecting PAX2 for the diagnosis of breast cancer
    Patent number: 8623617
    Abstract: A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio (the “Donald Predictive Factor” or “DPF”) in cells obtained from the breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with breast conditions. Also disclosed is a kit for monitoring breast conditions and determining drug resistance.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: January 7, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 8461101
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: June 11, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
    Patent number: 8461126
    Abstract: The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: June 11, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Compositions and methods for diagnosing, treating, and preventing prostate conditions
    Patent number: 8445444
    Abstract: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: May 21, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
    Patent number: 8431546
    Abstract: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: April 30, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Targeting PAX2 for the treatment of breast cancer
    Patent number: 8394780
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: March 12, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • DETECTING PAX2 FOR THE DIAGNOSIS OF BREAST CANCER
    Publication number: 20130023424
    Abstract: A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio (the “Donald Predictive Factor” or “DPF”) in cells obtained from the breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with breast conditions. Also disclosed is a kit for monitoring breast conditions and determining drug resistance.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 24, 2013
    Applicant: PHIGENIX, INC.
    Inventor: Carlton D. DONALD
  • DETECTING PAX2 FOR THE DIAGNOSIS OF BREAST CANCER
    Publication number: 20130023425
    Abstract: A method for monitoring breast conditions in a subject is disclosed. The method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio (the “Donald Predictive Factor” or “DPF”) in cells obtained from the breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with breast conditions. Also disclosed is a kit for monitoring breast conditions and determining drug resistance.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 24, 2013
    Applicant: Phigenix, Inc.
    Inventor: Carlton D. DONALD
  • TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS
    Publication number: 20120157508
    Abstract: The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
    Type: Application
    Filed: December 5, 2011
    Publication date: June 21, 2012
    Applicant: PHIGENIX, INC.
    Inventor: CARLTON D. DONALD
  • COMPOSITIONS AND METHODS FOR MONITORING AND DETECTING CANCEROUS CONDITIONS
    Publication number: 20120071347
    Abstract: A method for monitoring or detecting a prostate condition in a subject comprises determining Engrailed-2 (EN2) gene, Paired Box 2 (PAX2) gene, and/or ? defensin-1 (DEFB1) gene expression levels in a biological sample from the subject. The expression levels of EN2, PAX2 and/or DEFB1 gene are correlated with cancerous, pre-cancerous, or non-cancerous prostate conditions.
    Type: Application
    Filed: December 5, 2011
    Publication date: March 22, 2012
    Applicant: PHIGENIX, INC.
    Inventor: Carlton D. DONALD
  • COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING, AND PREVENTING PROSTATE CONDITIONS
    Publication number: 20120058130
    Abstract: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).
    Type: Application
    Filed: October 26, 2011
    Publication date: March 8, 2012
    Applicant: PHIGENIX, INC.
    Inventor: Carlton D. DONALD
  • Compositions and methods for diagnosing, treating, and preventing prostate conditions
    Patent number: 8088603
    Abstract: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: January 3, 2012
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald